These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1428744)

  • 21. Molecular modeling of hexakis(areneisonitrile)technetium(I), tricarbonyl eta5 cyclopentadienyl technetium and technetium(V)-oxo complexes: MM3 parameter development and prediction of biological properties.
    Wolohan P; Reichert DE
    J Mol Graph Model; 2007 Jan; 25(5):616-32. PubMed ID: 16769234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b.
    Cruciani G; Watson KA
    J Med Chem; 1994 Aug; 37(16):2589-601. PubMed ID: 8057302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers?
    Kim KH
    J Comput Aided Mol Des; 2007 Aug; 21(8):421-35. PubMed ID: 17646926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tautomerism in computer-aided drug design.
    Pospisil P; Ballmer P; Scapozza L; Folkers G
    J Recept Signal Transduct Res; 2003; 23(4):361-71. PubMed ID: 14753297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing the flexibility and adaptability of the DARC structural representation for computer-aided drug design.
    Sobel Y; Vizet P; Chemtob S; Barbieux F; Mercier C
    SAR QSAR Environ Res; 1998; 9(1-2):83-109. PubMed ID: 9517014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latest advances in molecular topology applications for drug discovery.
    Zanni R; Galvez-Llompart M; García-Domenech R; Galvez J
    Expert Opin Drug Discov; 2015; 10(9):945-57. PubMed ID: 26134383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecule kernels: a descriptor- and alignment-free quantitative structure-activity relationship approach.
    Mohr JA; Jain BJ; Obermayer K
    J Chem Inf Model; 2008 Sep; 48(9):1868-81. PubMed ID: 18767832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling robust QSAR.
    Polanski J; Bak A; Gieleciak R; Magdziarz T
    J Chem Inf Model; 2006; 46(6):2310-8. PubMed ID: 17125174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved QSARs for predictive toxicology of halogenated hydrocarbons.
    Trohalaki S; Gifford E; Pachter R
    Comput Chem; 2000 May; 24(3-4):421-7. PubMed ID: 10816012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the molecular modeling and quantitative structure-activity relationship-based design for antihistamines.
    Galvez J; Galvez-Llompart M; Zanni R; Garcia-Domenech R
    Expert Opin Drug Discov; 2013 Mar; 8(3):305-17. PubMed ID: 23289365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds.
    Marrero-Ponce Y; Casañola-Martín GM; Khan MT; Torrens F; Rescigno A; Abad C
    Curr Pharm Des; 2010; 16(24):2601-24. PubMed ID: 20642427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors.
    Tuccinardi T; Ortore G; Santos MA; Marques SM; Nuti E; Rossello A; Martinelli A
    J Chem Inf Model; 2009 Jul; 49(7):1715-24. PubMed ID: 19522467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QSAR and 3D-QSAR studies applied to compounds with anticonvulsant activity.
    Garro Martinez JC; Vega-Hissi EG; Andrada MF; Estrada MR
    Expert Opin Drug Discov; 2015 Jan; 10(1):37-51. PubMed ID: 25297377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QSAR modeling of anti-HIV activities of alkenyldiarylmethanes using topological and physicochemical descriptors.
    Leonard JT; Roy K
    Drug Des Discov; 2003; 18(4):165-80. PubMed ID: 15553927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and Design of Radiopharmaceuticals by
    Salahinejad M; Winkler DA; Shiri F
    Curr Radiopharm; 2022; 15(4):271-319. PubMed ID: 36045539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents.
    Shagufta ; Kumar A; Panda G; Siddiqi MI
    J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
    Peng T; Pei J; Zhou J
    J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of new anticancer drugs by computer-aided drug design.
    Neidle S
    Ann Oncol; 1994; 5 Suppl 4():51-4. PubMed ID: 8060897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues.
    González-Díaz H; Romaris F; Duardo-Sanchez A; Pérez-Montoto LG; Prado-Prado F; Patlewicz G; Ubeira FM
    Curr Pharm Des; 2010; 16(24):2737-64. PubMed ID: 20642428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.